Valsartan
Valsartan
1 active makers
soon
soon
soon
soon
US acquisition costNADAC · per unit
Average across 2 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
Valsartan
Average across 2 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Aurobindo Pharma Limited | unknown | 7 | SUPPLYING |
Shortages, recalls, and registration changes attached to this drug concept.
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product. — Recalling firm: Aurobindo Pharma USA Inc. — Product was distributed to major distribution chains throughout the United States.
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product. — Recalling firm: Aurobindo Pharma USA Inc. — Product was distributed to major distribution chains throughout the United States.
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product. — Recalling firm: Aurobindo Pharma USA Inc. — Product was distributed to major distribution chains throughout the United States.
CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million. — Recalling firm: Aurobindo Pharma USA Inc. — Product was distributed to 25 distributors and Retail Chains who may have further distributed the product throughout th…
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product. — Recalling firm: Aurobindo Pharma USA Inc. — Product was distributed to major distribution chains throughout the United States.